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http://dx.doi.org/10Atherosclerosis together with multiple sclerosis, psoriasis and rheumatoid arthritis can be
used as examples of chronic inflammatory diseases associated with multifactorial compo-
nents that evolve over the years. Nevertheless, an important difference between these
diseases relies on the fact that atherosclerosis develops from early ages where inflamma-
tion dominates the very beginning of the disease. This review highlights the inflammatory
nature of atherosclerosis and the role the immune system plays in the process of athero-
genesis. Although treatment of atherosclerosis has been for years based on lipid-lowering
therapies reducing a series of risk factors, the degree of success has been only limited
because cardiovascular complications related to the evolution of atherosclerotic lesions
continue to appear in the population worldwide. In this sense, alternative treatments
for atherosclerosis have come into play where both innate and adaptive immunity have
been proposed to modulate atherosclerosis-associated inflammatory phenomena. When
tested for their atheroprotective properties, several immunogens have been studied
through passive and active immunization with good results and, therefore, the strategy
through vaccination to control the disease has been made possible. Many experimental
pre-clinical studies demonstrating proof of concept that vaccination using DNA and
protein with an effective use of adjuvants and the optimal route of administration now
provide a tangible new therapeutic approach that sets the stage for several of these vac-
cines to be tested in large, randomized, long-term clinical studies. A vaccine ready for
human use will only be accomplished through the close association between academia,
regulatory government organizations and private industry, allowing the reality of a simple
and successful therapy to reduce atherosclerosis and its severe clinical complications.
 2015 IMSS. Published by Elsevier Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Key Words: Atherosclerosis, Immunomodulation, Vaccination.Introduction
According to the World Health Organization (WHO), coro-
nary atherosclerotic disease is the first cause of death
worldwide (1). The impact of this disease on population
mortality highlights how important it is to understand its
development in order to produce effective preventiverequests to: Jaime Mas-Oliva, Departamento de
a Estructural, Instituto de Fisiologıa Celular, Univer-
noma de Mexico, Apartado Postal 70-243, 04510
; Phone: (þ52) (55) 5622-5584; FAX: (þ52) (55)
as@ifc.unam.mx
 2015 IMSS. Published by Elsevier Inc. This is an open ac
).
.1016/j.arcmed.2015.06.004clinical measures. WHO calculates there are |20 million
deaths every year due to this disease whose treatment rep-
resents high costs for national health systems. It is esti-
mated that, by the year 2020, |300 million individuals
will die due to acute complications of this disease.
Atherosclerosis is a multifactorial condition including
factors such as hypertension, hypercholesterolemia, smok-
ing and aging (2). Nevertheless, increasing evidence
suggests that the significant damage provoked in the indi-
vidual by these risk factors is not limited to the atheroscle-
rotic process or its associated complications. Strict clinical
trials have proven that the manifestations of atherosclerosis
are a consequence of the ‘‘vulnerable’’ plaques prone tocess article under the CC BY-NC-ND license (http://creativecommons.org/
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make thrombi, the main cause of acute ischemic events in
both coronary and brain vessels (4).
Although most details about the onset of the atheroscle-
rotic plaque are still not clear, one of the postulates places
oxidative stress as one of the main causes for the onset of
the disease (5). Atherosclerotic lesions start as fatty streaks,
mainly consisting of foam cells surrounded by a layer of
endothelial cells with heterogeneous morphology (6).
Streaks are generally developed in areas where the perme-
ability of cell junctions is greater; such condition seems to
facilitate the passage of macromolecules from the tunica
intima to the tunica media of the vessel. In the early stages
of fatty streak formation, low-density lipoproteins (LDL)
are observed gathered in the subendothelial space before
foam cells appear, thus being the first initiator of this pa-
thology (7). Plaques become much more complex lesions
due to the development of fibrous tissue, calcification (8),
inflammation, ulceration of the arterial wall, and potential
hemorrhage. Occlusion by plaque growth is an important
risk factor, although it is the rupture or erosion of the
plaque that originates the thrombi leading to heart
infarction (9).
Lesions frequently affect the tunica intima of arteries
and are characterized by the deposit and infiltration of
diverse molecules and oxidized LDL (oxLDL) particles
(10) leading to inflammation, accumulation and prolifera-
tion of smooth muscle cells full of lipids (mainly
cholesteryl-oleate), macrophages converted into foam cells,
and fibrous tissue, which narrow the arterial lumen until
forming a lesion known as atheroma plaque. Many modifi-
cations have been described under these circumstances and
one of the most significant in the fatty streak stage is oxida-
tion, which may develop by exposure to reactive oxygen
species (ROS) generated in different reactions of normal
metabolism (11). Oxidative stress is paramount not only
during the start of the lesion, but also in the progression
of coronary heart disease. Diverse studies have postulated
that oxLDL accelerates the growth of atherosclerotic
lesions by inducing the expression of adhesion molecules,
chemokines and, in the long-term, apoptosis of endothelial
and smooth muscle cells (12).
Accumulation of lipoprotein particles is due not only to
an increased permeability of the endothelium, but also the
joining of other types of molecules to the arterial extracel-
lular matrix (frequently glycosaminoglycans), thus
increasing the time they stay within the arterial wall. Once
attached to the matrix, LDL particles undergo oxidative
modifications producing hydroperoxides, lysophospholi-
pids, oxysterols, and aldehydic products from the rupture
of fatty acids and phospholipids. Based on extensive
experimental evidence, it has been proposed that these
modifications represent one of the key pathological mecha-
nisms in the development of atherogenesis. Lipoprotein
deposits in the arterial wall also induce the accumulationof leukocytes, a critical step in lesion formation and, hence,
in the pathogenesis of the disease. Therefore, the process
known as atherogenesis involves inflammatory elements
from the start.
The types of inflammatory cells present in the evolving
atheroma include monocyte-derived macrophages as well
as lymphocytes. A number of adhesion molecules or leuko-
cyte receptors expressed on the surface of artery endothelial
cells participate in the recruitment of leukocytes towards
the nascent atheroma (13). Likewise, products of oxLDL
may raise the expression of leukocyte adhesion molecules
through pro-inflammatory cytokines involved in leukocyte
recruitment. For instance, interleukin 1 (IL-1) and tumor
necrosis factor-alpha (TNF-a) may induce expression of
P- and E-selectins on endothelial cells. Lipoprotein oxida-
tion products also may induce the release of pro-
inflammatory cytokines in vascular wall cells, providing
an additional link between the arterial accumulation of lipo-
proteins and leukocyte recruitment. Chemoattractant cyto-
kines such as chemokine (C-C motif) ligand 2 (CCL2),
also known as monocyte chemotactic protein-1, seem to
direct the migration of leukocytes in the arterial wall.Lipoproteins, Oxidative Stress and the Immune Response
Because the development of atherosclerosis is influenced by
innate and adaptive immune responses (14), several studies
have shown the activation of the immune system through
the different stages in the development of atherosclerosis.
A recent trial results suggest that activation of such immune
responses may promote atherosclerosis by inducing and
perpetuating arterial inflammation, whereas the selective
activation of certain immune functions may inhibit athero-
sclerosis and arterial inflammation. This suggests that new
approaches for the treatment and prevention of atheroscle-
rosis are likely to appear either by selective suppression of
pro-atherogenic immune responses or the selective activation
of anti-atherogenic immune responses. Numerous antigens
capable of triggering the immune response and affecting
the development of atherosclerosis have been identified so
far. These antigens together with the use of different classes
of adjuvants and different routes of administration may be
useful to modulate the immune response.
Trials assessing the effects of immunization on athero-
sclerosis have focused on two main objectives: 1) the pres-
ence of pre-existing immune responses considered part of
the pathologic process such as the immune response against
oxLDL epitopes and heat shock protein 60 (HSP 60); 2) tar-
gets like the cholesteryl-ester transfer protein (CETP) and
TNF-a. In the first case, the objective is to stimulate immune
responses that are protective per se but for which the magni-
tude is not strong enough unless they are increased, e.g., by a
vaccine that triggers a more effective immune response or by
inducing tolerance for undesired immune responses. In the
second case, the objective is to produce neutralizing
429Vaccines and Atherosclerosisantibodies that inhibit the effect of the chosen antigen.
Because the identification of key antigens responsible for
the activation of immune responses related to the develop-
ment of atherosclerosis is a pre-requirement for any immuni-
zation therapy, finding the right adjuvant and the most
appropriate administration route is also a challenge.
As for atherosclerosis, there is important evidence
showing that immune activation mainly involves pro-
inflammatory Th1 cells, considered responsible for disease
development (15). Therefore, adjuvants that favor a change
towards anti-inflammatory Th2 responses like aluminum
salt-based adjuvants and incomplete Freund’s adjuvant are
more effective than those favoring Th1 responses. Alterna-
tively, inhibition of Th1-mediated immune responses may
be accomplished through tolerance induction by mucosal
administration with or without adjuvants like the cholera
toxin B subunit (CTB) (16).
There is also evidence indicating that activation of Th1
immune responses enhances the aggressiveness of the dis-
ease and counteracts many immunoregulatory mechanisms.
If this concept is correct, it could be feasible to modulate
the process of the disease by activating or selectively inhib-
iting specific immune responses. Supporting this possibil-
ity, immunization of hypercholesterolemic animals with
oxLDL has proven to inhibit the process of atherosclerosis
(17) providing important evidence for a phenomenon of
atheroprotection through adaptive immune responses (18).
Figure 1 presents a summary of the mechanisms
involved in the development of an atherosclerotic lesionFigure 1. Schematic representation of current knowledge of biochemical procespresented so far. Accumulation of LDL particles in the in-
tima of an artery and their chemical transformation promote
the recruitment of monocytes (CD14hiCD16e) and T cells
that lead to adhesion molecule overexpression associated
with an increase in endothelial permeability. This phenom-
enon, associated with a lower migration rate of antigen-
presenting monocytes results in the accumulation of foam
cell macrophages and activation of T helper cells that even-
tually lead to the secretion of proinflammatory cytokines
(19). Together with these processes, resident dendritic cells
(CD11cþDCs) that mediate immunity and normally are
found in the intima of arteries start to overexpress cytokines
that promote the transformation of CD4þ T cells into
atherogenic Th-1 cells (20). Concomitantly, proliferation
and migration of smooth muscle cells are promoted in
response to growth factors and cytokine formation.
Many of the recent discoveries in relation to the physio-
pathology of atherosclerosis have radically changed the
traditional concepts related to the development of the dis-
ease. It is now clear that atherosclerosis corresponds to an
inflammatory disease where the immune system plays an
important role in its development, both during early stages
as well as during the late complications of the disease
(21e23). Therefore, a successful immunomodulatory ther-
apeutic strategy has to accomplish at least one of the
following points: 1) stop the growth of the atherosclerotic
plaque; 2) present the capability to accomplish total or par-
tial regression of the plaque; 3) stabilize the plaque; and 4)
stimulate conditions that diminish the inflammatory processses and immune activation involved in the development of atherosclerosis.
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the above, several approaches have been developed and
evaluated with the possibility of inhibiting atherosclerosis
by active immunization or directly providing antibodies
against proteins related to the development of the disease
(24). Because during the course of the disease, atheropro-
tective immunity is accomplished, the development of im-
munomodulation strategies and the evolution of a vaccine
in the prevention and/or treatment of atherosclerosis has
been considered a feasible approach (25,26).Development of Vaccines against Atherosclerosis
It has recently been reported that CD99, a membrane pro-
tein present in leukocytes, initially described to function
in T cell activation and aggregation of lymphocytes
(27e29), participates in human monocyte transmigration
through cultured endothelial cells (30). Whereas the recruit-
ment of T cells and monocytes contributes to the onset and
progression of atherosclerotic plaques, the blockage of this
transmigration process might constitute a protection against
the development of the disease; thus, the effect of vaccina-
tion of atherosclerosis-prone mice with CD99 was deter-
mined. This vaccine constructed by cloning the
extracellular domain of CD99 in pcDNA3, and adminis-
tered orally, significantly reduced the formation of athero-
sclerotic lesions in the aortic valve and the carotid
arteries when compared to mice immunized with the con-
trol vector.
Immunization of mice with vascular endothelial growth
factor receptor 2 (VEGFR2) also leads to a reduction of
atherosclerosis. The interference of the interaction of
VEGF with its main receptor VEGFR2 also results in
reduction of atherogenesis (31). Because VEGFR2 is ex-
pressed by activated endothelial cells covering the athero-
sclerotic plaque, the proatherogenic effect of this protein
lies in the fact that the recognition between VEGF and
VEGFR2 induces an inflammatory response in endothelial
cells through the activation of NF-kB (32). This activation
results in high levels of expression of adhesion molecules
such as VCAM 1, ICAM-1 and E-selectin, resulting in an
increase in the adhesion rate of monocytes to endothelial
cells (33). Therefore, a vaccination approach could atten-
uate both the initiation and progression of atherosclerosis
by reducing the expression of adhesion molecules by endo-
thelial cells (31).
An alternative approach has focused on the proprotein
convertase subtilisin/kexin type 9 (PCSK9), a protease sug-
gested to promote the degradation of the LDL receptor
(LDLR). Experiments employing antisense technology
have shown that PCSK9 inhibition resulted in an increase
in LDLR in the liver (34). These experiments suggest that
vaccination against PCSK9 might become a viable thera-
peutic strategy to reduce LDL in plasma (35). Recently,
several groups have used monoclonal antibodies raisedagainst PCSK9 in phase II studies using alirocumab and
evolocumab (36,37).
For years now, specific fragments of several apolipopro-
teins have also been used as an immunomodulation strategy
to control the development of atherosclerosis. Among these
apolipoproteins, regions between amino acids 45e76 and
12e35 of apolipoprotein C-III have been employed as im-
munogens in conjunction with T-helper epitopes and
tetanus toxin as carrier. It has been shown that induction
of an immune response or the use of antibodies against
these segments results in a reduction in atherosclerotic
lesions when tested in patients (38). Immunization of mice
with peptides derived from apolipoprotein B-100 (apo
B-100) also significantly reduced the development of
atherosclerosis (39). The most effective peptides identified
in these studies correspond to amino acids 661e680 (p45)
and 3136e3155 (p210). Pilot vaccines containing apo
B 100 p45 and p210, using aluminum salts as adjuvant
and bovine serum albumin as carrier, inhibit the develop-
ment of atherosclerosis in O50% of LDL receptor-
deficient mice expressing human LDL apo B-100 (40).
The use of peptides derived from apo B-l00 conjugated
with dialdehyde or malondialdehyde has also been shown
to be capable of eliciting an immune response against
non-native oxLDL by interacting with T cell antigen recep-
tors (TCRs) and used as a vaccine against atherosclerosis
(41e43).
Because CD4þ T cells have been postulated to be crit-
ical in the development of atherosclerosis, it has been
thought that they may also be involved in protective
immune reactions after immunization with oxLDL. This
possibility was studied in apolipoprotein E knockout (apoE
KO) mice and CD4/apoE double knockout mice immunized
with oxLDL. Results show that the absence of CD4þ T
cells in apoE KO mice leads to reduced atherosclerosis,
indicating that CD4þ T cells constitute a major proathero-
genic cell population. Therefore, the inhibition of CD4þ T
responses to peptides derived from apo B-100 has led to the
development of potential immunomodulatory methods to
treat atherosclerosis (44).
Although the role of oxLDL in the origin and progres-
sion of atherosclerosis is still far from clear, there is
evidence related to the presence of circulating antibodies
against oxidized lipoproteins in association with the disease
(45). Hypercholesterolemic rabbits immunized with homol-
ogous oxLDL presented an important reduced neointimal
area after balloon injury despite severe hypercholesterole-
mia (46). With this in mind and the fact that phosphoryl-
choline (PC) is an important component of a series of
inflammatory phospholipids such as platelet-activating fac-
tor (PAF) and oxLDL, several conjugates containing PC
have been tested correlating infection and atherosclerotic
lesion formation. Interestingly, it has been shown that Pneu-
mococcal immunization decreases atherosclerosis where
plasma from immunized mice shows the ability to block
431Vaccines and Atherosclerosisthe binding of oxLDL to macrophages. The production of
antibodies against oxLDL suggests molecular mimicry be-
tween epitopes of oxLDL and S. pneumoniae and therefore
the possibility that this type of immune response might pro-
duce protective effects (47). Another putative target for im-
munomodulation might be the lectin-like oxidized LDL
receptor-1 (LOX-1) as many of the pro-atherogenic action
of oxLDL occur through activation of LOX-1 (48,49).
Interestingly, C. pneumoniae, which accelerates atheroscle-
rosis in several animal models, has been shown to bind and
activate the LOX-1 receptor on endothelial cells and mac-
rophages (50).
Based on this experimental evidence, Table 1 presents a
list of patent applications and granted patents proposing
immunomodulatory procedures or vaccine formulations de-
signed to counteract atherosclerosis.Cholesteryl-ester Transfer Protein (CETP)
CETP is a hydrophobic glycoprotein consisting of 476 amino
acids playing an important role in lipid metabolism (64).
When this protein is overexpressed, it can lead to atheroscle-
rosis by decreasing high-density lipoproteins (HDL-C) and
increasing low-density lipoproteins (LDL-C) (65,66).
Because the inhibition of CETP activity has been proposed
to be a promising means for the attenuation of atheroscle-
rosis, several research groups have developed peptide and re-
combinant protein vaccines to induce specific antibodies
against CETP and reduce aortic lesions (67). The Hsp65-Table 1. Vaccine patent applications and granted patents presented as an alterna
Patent title
Vaccine therapies and prophylactic treatments
of atherosclerotic diseases
Fruchart et al.,
Vaccine for the treatment of atherosclerosis Fruchart et al.,
Vaccine therapy of atherosclerosis Mettens et al.,
Methods for increasing HDL cholesterol level Kwoh et al., 20
Immunotherapeutic treatment for inducing the
regression of atherosclerotic plaques
Carlsson and N
(WO20070257
Methods employing and compositions containing
plaque associated molecules for prevention and
treatment of atherosclerosis
Harats and Geo
Phosphorylcholine conjugates and corresponding antibodies De Faire and F
Peptide-based immunization therapy for treatment of
atherosclerosis and development of peptide-based assay
for determination of immune responses against oxidized
low density lipoprotein
Nilsson and Sh
Immunomodulatory compositions, methods and systems
comprising immunogenic fragments of apoB-100
Chyu and Shah
Immunomodulatory methods for treatment of atherosclerosis
via inhibition of CD4þ T cell response to apoB-100
Hanson, 2013 (
Fusion proteins and related compositions, methods and
systems for treatment and/or prevention of atherosclerosis
Nilsson et al.,
Peptide epitopes of apolipoprotein B Nilsson and Sh
Prevention and treatment of vascular disease with
recombinant adeno-associated virus vectors encoding
apolipoprotein A-I and apolipoprotein A-I Milano
Shah et al., 201CETPC vaccine was produced by fusing the heat shock pro-
tein 65 kDa (Hsp65) of Mycobacterium tuberculosis var.
bovis with the linear polypeptide epitope of the
cholesteryl-ester transfer protein C-terminal fragment
(CETPC) and expressed as soluble protein in Escherichia
coli. Because this vaccine was tested in the absence of adju-
vants, results obtained showed that the subcutaneous admin-
istration of this vaccine in mice triggered a low immune
response (66). The same group of investigators showed that
immunization of rabbits using the chimeric recombinant
enzyme rAnsB-TTP-CETPC containing asparaginase
(AnsB), the epitope of the T helper cell containing residues
831e854 of tetanus toxin (TTP) and the B cell epitope con-
taining residues 448e476 of human CETP (CETPC) in
Freund’s adjuvant, were able to overcome the problem of
low immune response. Because the use of Freund’s adjuvant
is unsuitable for human use due to its toxicity, rAnsB-TTP-
CETPC was used to immunize rabbits and stimulate produc-
tion of anti-CETP antibodies employing an adjuvant based
on aluminum salts, safe for human use. In this study, a high
titer of anti-CETP antibodies resulted in parallel with an in-
crease in HDL-C and a decrease in LDL-C, therefore
achieving an anti-atherogenic effect (68).
The development of a DNA vaccine against CETP has
also been achieved by using an eukaryotic expression con-
struction carrier containing eight CpG motifs 50-
GACGTT-30 and the immunostimulatory sequence and core
gene of the hepatitis B virus (HBc) inserted with a DNA
fragment encoding 26 amino acid residues (451e476) oftive to control the progression of atherosclerosis
Inventors Assignee Ref.
2003 (CA2458237 A1) GlaxoSmithKline Biologicals (51)
2004 (EP1267908 B1) GlaxoSmithKline Biologicals (52)
2004 (WO 2004080375 A2) GlaxoSmithKline Biologicals (53)
06 Avant Immunotherapeutics Inc (54)
ilsson, 2007
81 A2)
Bioinvent Int Ab (55)
rge, 2007 (US7279459 B2) Vascular Biogenics Ltd (56)
rostegard, 2011 (US8012483) Athera Biotechnologies Ab (57)
ah, 2011 (EP2305708A1) Forskpatent I SYD Ab (58)
, 2012 (WO2012065135 A2) Cedars-Sinai Medical Center (59)
US8609605 B2) Cardiovax LLC (60)
2013 (US 8506964) Cardiovax LLC (61)
ah, 2014 (US8647628 B2) Cardiovax LLC (62)
5 (US8926958 B2) Cedars-Sinai Medical Center (63)
432 Garcıa-Gonzalez et al./ Archives of Medical Research 46 (2015) 427e437the C-terminal region human CETP. Yuan et al. developed a
DNA vaccine against CETP, the pCR-X8-HBc-CETP
(abbreviated as pCETP) (69). This vaccine, administered
intramuscularly, inhibited the progression of atherosclerosis
in cholesterol-fed rabbits by inducing the synthesis of anti-
CETP antibodies. A noninvasive means of vaccination via
intranasal immunization has also been shown to be success-
ful (70). Whereas most intranasal vaccines induce poor im-
mune responses in the absence of immunostimulants or
presentation vehicles, a delivery system based on chitosan
has been developed. Chitosan has been extensively studied
for its compatibility, biodegradability, low cytotoxicity and
property of condensing DNA, making it able to protect
DNA from degradation. These studies showed that intra-
nasal immunization with chitosan/pCETP produces a
long-term systemic immune response (69). Therefore, it is
suggested that intranasal vaccination can be a convenient
and noninvasive route for delivery of DNA vaccines against
atherosclerosis.
From the several intranasal vaccines that are being
considered by the Food and Drug Administration (FDA)
in the U.S., the trivalent vaccine against influenza caused
by influenza virus subtypes A and B, commercially known
as FluMist, has been authorized for some years now. This
vaccine may be administered to persons between 2 and
49 years of age and does not require trained personnel to
do so (71). These results provide evidence that intranasal
vaccination is equivalent to intramuscular vaccination
regarding immunogenicity and support that the intranasal
route is a convenient noninvasive route for the administra-
tion of DNA therapeutic vaccines. Nevertheless, when
manufacturing a nasal DNA vaccine, it must be considered
that this route induces poor immunologic responses in the
absence of stimulants or delivery vehicles (72).
A dimerized synthetic peptide including residues
461e476 of human CETP and residues 830e843 of tetanus
toxoid TT (830e843) (CETPi-1) has been tested in parallel
with a mixture that uses a single peptide replacing TT
(830e843) for epitope aK-Cha-VAAWTLKAa (PADRE-
CETP), both formulated with different aluminum salt adju-
vants. Although differences in immunogenicity were found
due to the aluminum salt used, both showed an appropriate
anti-CETP antibody response (73,74). The CETPi-1
vaccine peptide corresponds to the acetate salt disulfide ho-
modimer of a synthetic peptide of 31 residues: C-QYI
KANSKFIGITE/FGFPEHLLVDFLQSLS. The 16-amino
acid sequence of C-terminal peptide is identical to residues
461e476 of the C-terminal sequence of human CETP pro-
tein, whereas the 14-amino acid N-terminal residues of the
peptide are identical in sequence to residues 830e843 of
tetanus toxin. This study was basically conducted in order
to demonstrate the safety and immunogenicity of CETP
in healthy adults. It was shown that a group of patients
who received a single administration test and a subgroup
of patients who received a booster acceptably toleratedthe vaccine at all doses. With a single injection, only one
patient developed anti-CETP antibodies with the highest
dose tested. Nevertheless, a second injection increased the
number of patients developing a dose-related immune
response. These results demonstrated that repeated admin-
istration of the vaccine is needed to induce an adequate
antibody response in order to inhibit CETP activity (75).
Other efforts focused on modulating the function of
CETP with a vaccine based on plasmid DNA encoding an
immunogenic fusion polypeptide that includes the nucleo-
tide sequence of at least one segment coding for a B cell
epitope of CETP connected to a helper T cell epitope
(76). A peptide-based vaccine for the regulation of CETP
activity comprising a fragment of a T cell epitope helper
connected to the fragment of a B cell epitope of CETP
has also been developed (77). Similarly, a method has been
proposed to increase the concentration of HDL by stimu-
lating an immune response that inhibits CETP through im-
munization with the complete CETP molecule conjugated
to a carrier such as Keyhole Limpet Hemocyanin or oval-
bumin (54). Table 2 presents a list of patent applications
and granted patents proposing immunomodulatory proce-
dures or vaccine formulations as an effort to counteract
the development of atherosclerosis.
Considering the problems shown by several of the tech-
nologies described above including the route of administra-
tion, cost and complexity of the formulation, our group has
designed and tested through preclinical studies a novel intra-
nasal anti-CETP vaccine. HB-ATV-8 vaccine is designed to
inhibit the development of atherosclerosis and its complica-
tions using a synthetic peptide as immunogen (81). This pep-
tide consists of the carboxy-end amino acids H486 to S496 of
CETP conjugated into a micellar nanoparticle system
formed by lipids derived from the cell membrane of archae-
bacteria, lysophospholipids and phospholipids (86,87).HB-ATV-8 Vaccine
The therapeutic efficiency of vaccine HB-ATV-8 was stud-
ied in our laboratory using New Zealand rabbits following
the requirements of the official Mexican regulation (NOM-
062-ZOO-1999) and the Committee for Institutional Care
and Use of Laboratory Animals (JMO63-15). In addition
to these norms, the Guide for Care and Use of Laboratory
Animals issued by the National Institutes of Health of the
U.S. was also observed. The normal diet consisted of
rabbit-specific food 5321 from LabDiet with the following
composition: crude protein not less than 16%; crude fat not
less than 2.5%; crude fiber not more than 18%; ash not
more than 8% and additional minerals not more than
2.1%. In the high-cholesterol diet, a mixture of 1% choles-
terol and 10% corn oil was added to the normal food. All
rabbits were fed ad libitum.
After the quarantine period, administration of the high-
cholesterol diet to the specific groups of experimental
Table 2. Vaccine patent applications and granted patents involving CETP presented as an alternative to control the progress of atherosclerosis
Patent title Inventors Assignee Ref.
A vaccine against cholesterol to prevent
hypercholesterolemia and atherosclerosis
Alving and Swartz Jr., 1992
(WO 1992010203 A1)
Alving CR (78)
Modulation of cholesteryl ester transfer
protein (CETP) activity
Ritterhaus and Thomas, 2003 (US6555113 B1) Avant Immunotherapeutics Inc. (77)
Plasmid-based vaccine for treating atherosclerosis Thomas LJ, 2005 (US6846808 B1) Avant Immunotherapeutics Inc. (76)
Modulation of cholesteryl ester transfer
protein (CETP) activity
Adari, Thomas and Ritterhaus, 2006
(US20060276400 A1)
Adari H, Thomas L, Ritterhaus CW (79)
Peptide-based vaccine compositions to endogenous
cholesteryl ester transfer protein (cetp)
Ritterhaus et al., 2008 (WO2008057529 A2) Coley Pharm Group (75)
Treatment of atherosclerosis Mattner and Schmidt, 2009
(US20090104211 A1)
Affiris Forschungs-Und Entwicklungs Gmbh (80)
Immunoenzymatic quantification method for
cholesterol ester transferring protein (CETP)
Alonso-Garcıa and Mas-Oliva, 2003
(US7749721 B2)
Universidad Nacional Autonoma de Mexico (81)
Anti-atheroma vaccine Kakkar and Lu, 2013 (US8435538 B2) Thrombosis Research Institute (82)
Treatment of atherosclerosis Brunner et al., 2013 (EP2190451 B1) Affiris AG (83)
Nasal vaccine against the development of
atherosclerosis and fatty liver
Mas-Oliva et al., 2014 (WO2014003531 A1) Universidad Nacional Autonoma de Mexico (84)
CETP fragments Brunner et al., 2014 (US 20140147456 A1) Affiris AG (85)
433Vaccines and Atherosclerosisanimals was started. After 15 days, vehicle and vaccine
administration to specific groups was started. For treated
animals, 50 ml of the vaccine preparation was nasally
administered twice weekly and treatment lasted for
3 months, after which experimental animals were sacrificed
using a lethal dose of sodium pentobarbital and processed
organ tissues.
The macroscopic aspect of livers from the control group
in comparison to animals fed a high-cholesterol diet was
found to be remarkably different because livers from this
last group presented a milky aspect (84). Importantly, vac-
cine treatment reversed this condition (84). Microscopi-
cally, the liver of the rabbits that received a normal diet
clearly show the laminar organization of normal hepatic pa-
renchyma forming liver lobules with plates of hepatocytes
radiating between the central vein and radially arranged si-
nusoids (Figure 2A). In contrast, the liver from rabbits fed a
high-cholesterol diet for 3 months who received no vaccine
showed a varied degree of micro- and macrovesicular hepa-
tocellular damage and diffuse steatosis affecting large areas
of the liver lobules and mainly hepatocytes surrounding the
central vein (Figure 2B). Some of these hepatocytes show
cytoplasm distention due to the presence of lipid droplets
in their cytoplasm. Most hepatocytes from the lobular pe-
riphery close to the portal triads present a normal appear-
ance although some of them show a microvacuolar
cytoplasm. In some areas, lipid droplets coalesce becoming
a vacuole of fat that displaces the nucleus to the periphery
of the cell. In general, images show a combination of stea-
tosis, the presence of polymorphonuclear leukocytes,
monocytes or both, ballooned hepatocytes and areas of ne-
crosis. Livers from rabbits that received the vaccine prepa-
ration simultaneously to the high-cholesterol diet during the
3-month period show centrilobular hepatocytes with some
degree of vacuolization without hepatocyte ballooning,whereas periportal and paracentral hepatocytes practically
show a normal appearance (Figure 2C). Administration of
the vaccine simultaneously with the initiation of the high-
cholesterol diet shows a protective effect on the hepatic
parenchyma. In order to evaluate the degree of fibrosis
developed with a high cholesterol diet, the Masson tri-
chrome staining technique was implemented. Histological
liver sections of a control animal fed on normal diet demon-
strate the scarce presence of collagen fibers around the wall
of central vein but not around the sinusoids (Figure 3A). In
contrast, livers from animals fed a high-cholesterol show an
important development of perisinusoidal fibrosis close to
the central vein and at the central vein itself (Figure 3B).
These changes are more frequently observed in zone III
of the hepatic acinus, corresponding to the center of the
classical lobule. An association between the presence of
ballooned hepatocytes and perisinusoidal fibrosis near the
central vein was frequently observed (Figure 3B). On the
other hand, administration of the vaccine concomitantly
with the high-cholesterol diet significantly improved the
histopathological appearance of the livers as shown in
Figure 3C.
Figure 4 shows the histological analysis in a cross-
section of the abdominal aortas of the same rabbits fed
a normal diet (Figure 4A), a high-cholesterol diet without
treatment (Figure 4B) or a high-cholesterol diet fed
concomitantly with the intranasal administration of the
vaccine (Figure 4C). Interestingly, this last group of
treated experimental animals show histological character-
istics remarkably similar to the control group in contrast
to animals fed the high-cholesterol diet that presents sig-
nificant lesions in the intima of arteries. These results, first
described as part of a patent application (84), indicate the
important degree of protection shown by the HB-ATV-8
vaccine, not only upon the development of lesions in the
Figure 3. Masson trichome-stained histological sections of livers from
experimental animals. (A) Control rabbits that received a normal diet.
(B) Rabbits fed a high cholesterol diet for 3 months and received no treat-
ment. (C) Rabbits fed for 3 months with a high cholesterol diet that simul-
taneously received the vaccine preparation. CV, central vein. Images x200.
Figure 2. Hematoxylin- and eosin-stained histological sections of livers
from experimental animals. (A) Control rabbits that received a normal diet.
(B) Rabbits fed a high cholesterol diet for 3 months and received no treat-
ment. (C) Rabbits fed for 3 months with a high cholesterol diet that simul-
taneously received the vaccine preparation. Images x1000.
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development of fatty liver in the group of experimental
animals fed the high cholesterol diet. These encouraging
results now extended to the porcine model and long-term
experimentation has shown that vaccination importantly
prevents the process of atherogenesis and the development
of fatty liver, allowing us to further test this technological
platform starting with clinical trials in the near future.
One of the novel aspects of this formulation is the use of
lipids from archaebacterial cell membranes as a vaccinecomponent. Use of these preparations has shown not only
to function as humoral adjuvants but also to promote a
strong cytotoxic T-cell immune response characterized by
a long-term memory (88). Although it has been reported
that the immune response obtained employing archaebacte-
rial lipids is similar to that obtained with the potent, yet
toxic, Freund’s adjuvant, preparations using lipids derived
from archaebacteria are not toxic (89e93). Use of these
particular lipids in association with lysophospholipids
allowed us to prepare micellar nanoparticles homogeneous
Figure 4. Hematoxylin- and eosin-stained histological sections of abdom-
inal aorta from experimental animals. (A) Control rabbits that received a
normal diet. (B) Rabbits fed a high cholesterol diet for 3 months and
received no treatment. (C) Rabbits fed for 3 months with a high cholesterol
diet that simultaneously received the vaccine preparation. Images x160.
435Vaccines and Atherosclerosisin size showing good stability and, more importantly,
maintenance of the native a-helicoidal secondary structure
of the antigen, a key feature required to observe positive
immunological responses (86).Perspectives
Taking into account the promising results observed with
many of the immunomodulatory therapies presented above
at the pre-clinical level, it is critical to use this new-found
knowledge related to immunity and inflammation in athero-
sclerosis to guide clinical testing. These therapies have the
potential to directly treat atherosclerosis by targeting pro-
teins at the arterial wall and lipoproteins, in comparison
to the current pharmacological approach mainly designed
to counteract risk factors such as hypercholesterolemia, hy-
pertriglyceridemia and hypertension. In this respect, induc-
tion of self-immune responses through the use of
autoantigens represents a promising approach to understand
the relationship between innate and adaptive immunity withregard to recognition by immune receptors and the expres-
sion of protective antibodies.Acknowledgments
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